Signaturefd LLC Purchases 636 Shares of The Allstate Co. (NYSE:ALL)

Signaturefd LLC raised its position in The Allstate Co. (NYSE:ALL) by 17.9% in the 4th quarter, Holdings Channel reports. The firm owned 4,184 shares of the insurance provider’s stock after buying an additional 636 shares during the period. Signaturefd LLC’s holdings in Allstate were worth $586,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Lindbrook Capital LLC increased its stake in Allstate by 37.6% in the fourth quarter. Lindbrook Capital LLC now owns 1,274 shares of the insurance provider’s stock valued at $178,000 after purchasing an additional 348 shares in the last quarter. DT Investment Partners LLC increased its stake in Allstate by 7.7% in the fourth quarter. DT Investment Partners LLC now owns 3,834 shares of the insurance provider’s stock valued at $537,000 after purchasing an additional 274 shares in the last quarter. abrdn plc boosted its holdings in shares of Allstate by 70.0% in the fourth quarter. abrdn plc now owns 109,903 shares of the insurance provider’s stock valued at $15,384,000 after buying an additional 45,254 shares during the period. WP Advisors LLC acquired a new position in shares of Allstate in the fourth quarter valued at approximately $218,000. Finally, Wetzel Investment Advisors Inc. acquired a new position in shares of Allstate in the fourth quarter valued at approximately $504,000. Institutional investors own 76.47% of the company’s stock.

Insider Activity

In other news, CAO John C. Pintozzi sold 4,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $159.47, for a total value of $637,880.00. Following the transaction, the chief accounting officer now directly owns 10,736 shares of the company’s stock, valued at $1,712,069.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider John E. Dugenske sold 31,000 shares of the firm’s stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $170.20, for a total transaction of $5,276,200.00. Following the transaction, the insider now directly owns 63,731 shares of the company’s stock, valued at $10,847,016.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO John C. Pintozzi sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $159.47, for a total transaction of $637,880.00. Following the transaction, the chief accounting officer now directly owns 10,736 shares in the company, valued at $1,712,069.92. The disclosure for this sale can be found here. Insiders own 1.80% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ALL shares. The Goldman Sachs Group upped their price target on shares of Allstate from $164.00 to $195.00 and gave the company a “buy” rating in a report on Monday, March 25th. Jefferies Financial Group upgraded shares of Allstate from a “hold” rating to a “buy” rating and increased their target price for the stock from $130.00 to $180.00 in a report on Tuesday, January 9th. BMO Capital Markets increased their target price on shares of Allstate from $140.00 to $158.00 and gave the stock a “market perform” rating in a report on Friday, January 19th. UBS Group increased their target price on shares of Allstate from $171.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Finally, Keefe, Bruyette & Woods increased their target price on shares of Allstate from $181.00 to $189.00 and gave the stock an “outperform” rating in a report on Wednesday, April 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.71.

Allstate Stock Performance

NYSE ALL opened at $175.27 on Wednesday. The firm has a market capitalization of $46.11 billion, a P/E ratio of -141.35, a price-to-earnings-growth ratio of 0.42 and a beta of 0.52. The firm’s fifty day moving average price is $164.50 and its two-hundred day moving average price is $148.42. The Allstate Co. has a 1 year low of $100.57 and a 1 year high of $176.93. The company has a current ratio of 0.37, a quick ratio of 0.37 and a debt-to-equity ratio of 0.51.

Allstate (NYSE:ALL) last issued its quarterly earnings data on Thursday, February 8th. The insurance provider reported $5.82 earnings per share for the quarter, beating the consensus estimate of $3.87 by $1.95. The company had revenue of $14.83 billion for the quarter, compared to analyst estimates of $12.69 billion. Allstate had a negative net margin of 0.33% and a positive return on equity of 2.67%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.36) earnings per share. As a group, research analysts anticipate that The Allstate Co. will post 13.44 EPS for the current year.

Allstate Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Monday, March 4th were given a $0.92 dividend. The ex-dividend date was Friday, March 1st. This is a positive change from Allstate’s previous quarterly dividend of $0.89. This represents a $3.68 annualized dividend and a dividend yield of 2.10%. Allstate’s dividend payout ratio is presently -296.77%.

Allstate Company Profile

The Allstate Corporation, together with its subsidiaries, provides property and casualty, and other insurance products in the United States and Canada. It operates in five segments: Allstate Protection; Protection Services; Allstate Health and Benefits; Run-off Property-Liability; and Corporate and Other segments.